|
Patent landscape, scope, and claims: |
United States Patent 10,806,743 (Lactitol Plasma Reduction After High-Fat/High-Calorie Meals): Claim Scope, Patent-Protection Boundaries, and US Landscape
Executive summary: US Patent 10,806,743 claims a narrow, meal-dependent lactitol pharmacokinetic control method: administer lactitol after a meal that is “high fat” (and, in dependent claims, “high calorie” with specific calorie and fat attribution thresholds) to reduce plasma lactitol concentration with explicit dose ranges and a quantitative PK endpoint (plasma lactitol <1,000 ng/mL at 4 hours). The claim set also narrows by dosage form (powder/tablet/liquid), administration mode (powder reconstituted in specified liquids), splitting dosing schedules, and optional co-administration of specific laxative/osmotic agents. Practical freedom-to-operate turns on whether a competitor’s regimen uses the same postprandial condition (high-fat/high-calorie meal), dose range (including the 21 g specific dose), dosing schedule (one vs two+), and PK target.
What does US Patent 10,806,743 claim about reducing lactitol plasma concentration after meals?
Core independent claim (Claim 1)
- Preamble/goal: “A method of reducing plasma concentration of lactitol in a subject”
- Trigger condition: administering lactitol after the subject has consumed a meal
- Meal characterization: the meal is a “high fat meal”
- Intervention: administering a total dose of an effective amount of a formulation comprising lactitol
Litigation-relevant scope boundaries
- Meal timing is mandatory. The lactitol must be given after meal consumption. Pre-meal or fasting dosing does not fall within Claim 1 as written.
- Meal type is mandatory. The meal must be high fat. The claim does not define a numeric fat percentage in Claim 1 itself, but dependent claims add numeric constraints (see Claims 2–4).
- Endpoint is functional. The claim is framed as “reducing plasma concentration.” That creates two claim-construction pressure points:
- If “reduce” is interpreted as comparative to baseline, competitors may attempt to argue their regimen does not achieve reduction under a cited comparator.
- If “reduce” is treated as an inherent outcome of the method, it may lower the need for explicit comparative reference in enforcement, but Claim 21 (with a numeric threshold) strengthens enforceability by adding an objective PK limit in a dependent claim.
How do the dependent claims narrow the “high fat meal” requirement in US 10,806,743?
What “high calorie” thresholds are claimed (Claims 2–4)?
The dependent claim chain converts the qualitative “high fat meal” in Claim 1 into a quantitative condition:
- Claim 2: meal is a high calorie meal
- Claim 3: high calorie meal comprises at least about 500 calories
- Claim 4: about 50% of the calories attributable to fat
Scope impact
- Claim 1 covers any high-fat meal, even if not explicitly “high calorie” or 50% fat. Enforcement under Claim 1 could focus on evidence that a given meal is “high fat.”
- Claims 2–4 create a more enforceable sub-scope with objective meal metrics. Any competitor protocol that uses lower calorie meals, or fat content meaningfully below the 50% caloric contribution, can design around those dependent claims while still potentially implicating Claim 1 (unless Claim 1 is also contested with meal-definition arguments).
What does this mean for design-around meal composition?
- Moving to a meal that is not “high fat” (even if calorically dense) is the cleanest avoidance tactic for Claim 1.
- A meal that meets calories but not fat contribution can avoid Claims 2–4, but not necessarily Claim 1.
How do the dose-range and dosing-schedule claims constrain lactitol exposure in the patent?
What lactitol total doses are claimed (Claims 7–9)?
- Claim 7: lactitol about 5.0 g to about 30 g
- Claim 8: lactitol about 10.0 g to about 25 g
- Claim 9: lactitol about 21.0 g (single-point example claim)
Scope impact
- Claims 7 and 8 create broad numeric ranges that cover many practical regimen totals for lactitol-based laxative/constipation strategies.
- Claim 9 can serve as a “hook” for enforcement if a competitor uses a ~21 g total lactitol dose after a high-fat meal.
Design-around
- A regimen using total lactitol outside Claim 7 (below ~5 g or above ~30 g) avoids these numeric-dependent claims, but again Claim 1 still requires “effective amount.” Depending on claim construction, “effective amount” could still capture outside numeric ranges if “effective” is established.
- If a competitor uses a dose within Claim 7 but uses a meal condition that is not high fat, the claims are still avoided at the meal step.
How is dosing split treated (Claims 10–11)?
- Claim 10: effective amount divided into two or more doses
- Claim 11: divided into two doses
Scope impact
- Claim 10 covers both two-dose and multi-dose schedules, but Claim 11 narrows to exactly two doses.
- A once-daily single-dose regimen could fall outside Claims 10–11 while still being within Claim 1 if Claim 1 does not require splitting (it does not).
Design-around
- Using a single bolus dose after a high-fat meal may avoid Claims 10–11, but not Claim 1.
What formulation formats are covered (Claims 5, 6, 13, 15)?
Powder, reconstitution, liquid, tablet
- Claim 5: formulation administered as a powder
- Claim 6: powder is reconstituted in a solution selected from:
- juice
- soda
- water
- balanced electrolyte solution
- Claim 13: formulation is liquid
- Claim 15: formulation is a tablet
Scope impact
- Claim 1 is broad to “a formulation comprising lactitol,” but dependent claims tie protection to specific dosage forms and specific reconstitution vehicles.
- If a competitor sells lactitol as a tablet taken after a high-fat meal, that maps to Claim 15. If they use a powder mixed with, say, milk or a specific beverage not listed, that could help avoid Claim 6 but still potentially implicate Claim 5 (powder) and Claim 1.
Do the co-administered agents expand the method scope (Claims 16–17)?
- Claim 16: method further comprising administering an agent selected from:
- polyethylene glycol
- sulfate salts
- magnesium salts
- stimulant laxatives
- lubiprostone
- Claim 17: the osmotic agent is lubiprostone
Scope impact
- These dependent claims cover combination therapy, but the selection set is limited to those named agents.
- A competitor combination that uses different classes (eg, bile acid sequestrants, secretagogues other than lubiprostone, guanylate cyclase-C agonists, etc.) would not fall within Claims 16–17, though it could still infringe Claim 1 depending on whether those agents are required for the method (Claims 16–17 say “further comprising,” so Claim 1 can stand alone without co-therapy).
What bowel-movement condition is claimed (Claims 18–19)?
- Claim 18: subject has three or more spontaneous bowel movements
- Claim 19: spontaneous bowel movements occur within a seven-day period
Scope impact
- These dependents are outcome/condition based. If a competitor’s protocol does not track “spontaneous bowel movements” as defined, enforcement can turn on evidentiary standards in the comparator population and endpoints.
- If the method is used for constipation and includes the requisite bowel movement metrics, these dependent claims tighten enforcement.
What PK numeric endpoint is claimed (Claim 21)?
- Claim 21: subject has plasma lactitol concentration < 1000 ng/mL four hours after administration
Scope impact
- This is the most objectively enforceable element in the excerpt you provided.
- A competitor could still fall within Claim 1 but avoid Claim 21 if their lactitol plasma concentrations at 4 hours are at or above 1,000 ng/mL under comparable conditions (high-fat meal, dose, formulation).
Practical litigation posture
- Infringement of Claim 21 will likely require plasma sampling and assay comparability. Claim 21 functions like an evidentiary “litmus test” in addition to a mechanistic goal (“reduce plasma concentration”).
Claim-to-practice mapping: what a competitor would need to do to infringe?
Below is a compact infringement checklist aligned to the claims you provided.
| Claim element |
Required for Claim 1? |
Typical design-around levers |
| Lactitol administered after a meal |
Yes |
Dose before meal, fasting dosing, or altered timing |
| Meal is “high fat meal” |
Yes |
Use meal composition not meeting “high fat” characterization |
| PK “reduction” objective |
Yes (functional) |
Show no reduction vs baseline/control; challenge comparator and interpretation |
| Total dose “effective amount” |
Yes |
Use non-effective amount and argue lack of reduction (risk if “effective” broad) |
| Powder/tablet/liquid forms |
Only for dependents |
Switch dosage form; change reconstitution vehicle |
| High calorie thresholds (≥500 calories and 50% fat) |
Only Claims 2–4 |
Use lower calories or lower fat caloric contribution |
| Dose numeric ranges (5–30 g; 10–25 g; 21 g) |
Only Claims 7–9 |
Use totals outside numeric ranges; avoid 21 g dose |
| Split dosing (2+ or exactly 2 doses) |
Only Claims 10–11 |
Single dose |
| Co-administered agent set |
Only Claims 16–17 |
Avoid named agents, use different combination therapy |
| Spontaneous bowel movement outcome |
Only Claims 18–19 |
Different endpoints, not “spontaneous,” or outside timing window |
| Plasma lactitol <1000 ng/mL at 4 hours |
Only Claim 21 |
Adjust formulation/dose/mealtime to exceed threshold |
How strong is the patent estate for this specific lactitol postprandial PK control approach?
From the claim text alone, the enforceability strength is driven by:
- Multiple dependent claims that introduce objective numeric constraints (fat contribution; ≥500 calories; dose ranges; 21 g point; PK <1,000 ng/mL at 4 hours).
- A narrow context limiting infringement to post-meal high-fat regimens, which reduces the universe of infringing uses but increases the clarity of what “counts” in contested products.
Likely weak points to scrutinize in enforcement (claim-construction risks):
- “High fat meal” in Claim 1 is qualitative without a numeric definition. Enforcement may require expert evidence establishing that a regimen’s meal meets “high fat” as used in the patent.
- “Reducing plasma concentration” is functional. If a competitor can show their regimen does not reduce relative to a proper comparator, they can attack Claim 1.
- Dependent claims are avoidable by changing one variable: meal metrics, dose totals, split dosing, formulation vehicle, or the co-administered agent set.
What would an “Orange Book” status likely be for a lactitol method patent like this?
A method-of-treatment patent typically does not map cleanly onto traditional drug product “Orange Book” listings in the same way as formulation or composition patents. Orange Book listings track patents that claim the drug product and are listed for the NDA/ANDA. Your provided information includes only the US patent and its claim text, not the associated NDA/ANDA, drug product listing, or patent type that would determine Orange Book mechanics.
Net effect for business planning: treat 10,806,743 as a potentially Orange-Book-adjacent risk depending on whether the patent is listed for a specific lactitol NDA/ANDA and whether the claimed method is tied to the labeled condition and product label directions.
What generic or biosimilar entry risks exist for this patent?
This is not a biologic or a biosimilar scenario. The main entry risk is generic lactitol products (ANDA) or product-labeling strategies that could practice the claimed postprandial high-fat dosing method.
Risk drivers
- Competitors practicing the same method (same meal condition, dosing, form) can face infringement even with generic products if the patented method is carried out.
- The PK endpoint suggests that if generic firms rely on labeling and expected PK similar to branded products, they may still practice the claimed method.
Lower-risk entry paths
- Product labels that steer away from “high fat meal” timing or specify a different administration condition can reduce practical infringement.
- Using alternative dosing regimens outside the dose ranges or non-matching formulation/vehicle may avoid dependent claims.
What litigation and settlement patterns would be most relevant to this type of method claim?
Method claims like this often resolve via:
- Design-around reformulations/labeling that keep active ingredient constant but change the regimen variables (meal condition, dose split, vehicle).
- Evidentiary battles around plasma concentration comparisons (for Claim 21 especially) and how “reduce” is measured.
Because your input contains only claim text and not the case docket, parties, or settlement terms, no docket-level mapping is possible here.
Key takeaways
- US 10,806,743 Claim 1 protects a specific postprandial strategy: administer lactitol after a high-fat meal to reduce plasma lactitol concentration.
- Dependent claims add objective constraints that materially narrow the infringement set: high-calorie meal ≥500 calories with ~50% calories from fat, dose ranges 5–30 g and 10–25 g, and a named 21 g total dose.
- The patent also has strong evidentiary leverage via Claim 21: plasma lactitol <1,000 ng/mL at 4 hours.
- Design-around options are clear and variable-based: alter meal fat/calorie composition, timing, split dosing, dosage total, dosage form and reconstitution vehicle, and avoid the named combination agents.
- Commercial risk is highest where a competitor will actively practice the method consistent with labeled or study protocols that mirror the claimed regimen.
FAQs
-
Can a competitor infringe US 10,806,743 by using a tablet if the independent claim only requires “formulation”?
Yes, Claim 1 covers any lactitol formulation; dependent Claim 15 separately covers tablet administration.
-
Does avoiding the 21 g lactitol dose avoid all infringement risk?
It can avoid Claim 9 specifically, but not Claims 1 or 7–8 if the total dose still falls within broader ranges and the meal condition remains high fat.
-
If a meal is “high calorie” but not “high fat,” does the patent still apply?
Claims 2–4 would likely be avoided. Claim 1 still requires “high fat,” so the key is meeting the “high fat meal” characterization.
-
Is the PK endpoint in Claim 21 necessary to infringe Claim 1?
Claim 21 is a dependent claim, so it is required only to infringe that dependent scope, not Claim 1.
-
Would switching the beverage used to reconstitute a powder avoid the patent?
It may avoid dependent Claim 6 if the vehicle is outside juice, soda, water, or balanced electrolyte solution, while still potentially implicating Claim 5 and Claim 1.
References
- US Patent 10,806,743. “Method of Reducing Plasma Concentration of Lactitol After High Fat Meal.” Claims provided in prompt.
More… ↓
⤷ Start Trial
|
